Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?

J Clin Oncol. 2004 May 15;22(10):2035-6; author reply 2036-7. doi: 10.1200/JCO.2004.99.337.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Confounding Factors, Epidemiologic
  • ErbB Receptors / administration & dosage
  • ErbB Receptors / metabolism*
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Quinazolines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Quinazolines
  • ErbB Receptors
  • Gefitinib